# Research (30%)

1. **Summary**

Since her initial appointment, Dr. \*\*\*\* has focused on research related to food allergy and mucosal immunology. Dr. \*\*\*\* has been involved in therapeutic trials for food allergy for her entire career, including enrolling the first peanut and egg oral immunotherapy (OIT) research participants in clinical trials in the United States during her Fellowship at \*\*\*\* University. During her early faculty appointment at UAMS, she capitalized on strong local research mentorship from established laboratory and basic science researchers focused on bacterial immunopathogenesis, mucosal immune responses and T-cell regulation to hone her laboratory and research skills. This collaborative work led to a funded NIH/NIAID Mentored Clinical Scientist Career Development Award (K08) focused on T-cell immunoregulatory networks and provided Dr. \*\*\*\* with a strong research foundation. Because of her continued interest and work in food allergy research and to better align her clinical and research efforts, Dr. \*\*\*\* has subsequently focused primarily on clinical and translational investigation in food allergy, applying the knowledge she gained from this early work and building productive collaborative research networks.

# Translational and Clinical Research in Food Allergy

Dr. \*\*\*\* is a nationally recognized expert in food allergy, with particular expertise in novel therapies, including oral immunotherapy (OIT), sublingual immunotherapy (SLIT), epicutaneous immunotherapy (EPIT) and application of novel biologics for treatment of food allergy. The original investigator-initiated research in egg and peanut OIT initiated by Dr. \*\*\*\* and her colleagues provided important foundational insights that have been built upon in multi-center clinical trials, ultimately leading to licensure of the first FDA-approved therapy for peanut allergy, Palforzia® produced by Aimmune Therapeutics. Dr. \*\*\*\* has been a co-investigator in the NIH-funded Consortium for Food Allergy Research (CoFAR) since its inception in 2005 and has taken on additional leadership within the consortium as a member of the Steering Committee and Conflict of Interest Committee. She has also served as Principal Investigator (PI) or Co- Investigator (Co-I) on multiple clinical research protocols involving therapeutic interventions in food-allergic children and adults. Dr. \*\*\*\* is currently the PI for the Food Allergy Research and Education (FARE) Clinical Network Discovery Center of Distinction which is funded through 2025. The FARE Clinical Network is the leading organization supporting clinical care and research in food allergy and has facilitated numerous advances in the field.

The Arkansas Children’s Food Allergy Clinical and Research Program has been leading innovative research and clinical trials in food allergy for the past three decades through NIH- funded, investigator-initiated, and industry-sponsored multi-center trials in food allergy. Dr. \*\*\*\* is the Associate Director of the program and helps lead a center that combines a skilled clinical research team adept at food allergy clinical trials, with established leadership, experience, and expertise in food allergy immunotherapeutics. Dr. \*\*\*\*’s contributions in the field of food allergy and successes in mentoring the next generation of academic physicians provides a strong foundation for continued expansion and advancement to assure future productivity and programmatic success.

# Mucosal Immunoregulatory Networks During Chlamydial Infection

During her early career, Dr. \*\*\*\* capitalized on strong basic science mentorship at UAMS to investigate mucosal T-cell immunoregulatory networks in chlamydia infection models, work that was funded by an NIH Mentored Clinical Scientist Career Development Award (K08). This research provided a foundation for application of knowledge gained from studying pathologic and protective mucosal immune responses in infection models to exploration of immunoregulatory networks in food allergic disease. *Chlamydia trachomatis* sexually transmitted infections (STI) are the most common bacterial STIs in the United States and worldwide and represent a significant public health concern due to their adverse effects on reproduction. Complications of this common STI, such as infertility and ectopic pregnancy, can be devastating and there are no reliable biomarkers to predict adverse disease outcomes. CD4+ T-helper type 1 (Th1) responses are

critical for resolution of infection, however these responses also result in reproductive tract pathology. Dr. \*\*\*\*’s work examined the contribution of distinct effector and regulatory T-cell subsets in resolution of infection and development of genital tract pathology resulting in peer- reviewed publications, presentations at scientific meetings and a strong research foundation in mucosal immunology.

# External Collaborations

Dr. \*\*\*\* has leveraged strong collaborative networks through the FARE Clinical Network, the NIH/NIAID Consortium of Food Allergy Research, and collaborative multi-center industry trials to advance care and treatment for individuals with food allergy. In addition to these national networks, Dr. \*\*\*\* and Dr. Drew Bird from University of Texas Southwestern and Children’s Medical Center in Dallas have developed the Food Allergy Collaborative of Texas and Arkansas (FACTA) to strengthen regional collaboration in food allergy investigation.

# Future Research Plans

Building on a foundation of success in the Arkansas Children’s Food Allergy Clinical and Research Program, Dr. \*\*\*\* plans to continue investigation of novel, next-generation therapies for individuals with food allergy using innovative approaches in collaboration with a nationwide network of experts. She is also interested in the impact of food allergy on mental health, resilience, and quality of life, particularly during the COVID-19 pandemic and has initiated a multi-center study with Dr. Drew Bird at UTSW to investigate this topic. Because of her long- standing interest in social determinants of health in food allergy, she has a developing collaboration with the Food Equality Initiative, one of the nation’s leading organization working to increase access to allergy friendly and gluten free foods for food-allergic, food-insecure individuals with food allergy and other disorders requiring restricted diets using their novel online delivery platform. Dr. \*\*\*\* will continue her leadership and involvement with the FARE Clinical Network with two novel food allergy therapeutic clinical trials set to begin in the next 3-4 months and an additional pilot project starting in the next 6-12 months. Dr. \*\*\*\* is committed to advancing the food allergy program’s overall mission to provide state-of-the art clinical care while advancing knowledge and new discovery toward therapeutic interventions and improved quality of life for food allergic individuals.

# Invited Reviewer

Dr. \*\*\*\* has served on national grant review panels including the Department of Defense, Congressionally Medical Research Program, Peer Reviewed Medical Research Program, Food Allergy Review Panel and the Food Allergy Research and Education (FARE) Discovery Center of Distinction Pilot Project Review Panels for 1) Food Allergy Immunotherapy; 2) Eosinophilic Esophagitis; 3) Biologics; 4) Patient-Centered Outcomes. She has been an expert reviewer for 8 journals.

# Research Funding

Dr. \*\*\*\* and her team have been successful in securing funding for their research efforts. She has received a total of $19,971,110 in extramural funding as a PI or Co-investigator. Dr. \*\*\*\* has been PI or Co-I on 44 clinical trials in food allergy with total funding of $5,880,204 (Principal Investigator- $1,230,628, Co-Investigator- $4,649,576). Due to her expertise in food allergy, Dr. \*\*\*\* has been asked to participate as a site lead investigator for 2 pending NIH awards, a U44 application evaluating a novel therapy for peanut allergy and a U01 application evaluating a food allergy prevention strategy using probiotic therapy in food allergy. In addition, a pilot project through the FARE Clinical Network Discovery Center of Distinction will be implemented over the next 6-12 months.

# Extramural Funding-Principal Investigator

American Academy of Pediatrics 2001 Resident Research Grant, **PI: AM \*\*\*\***. “Clinical Correlation of Asthma Severity with Beta-2-Adrenoreceptor Polymorphisms”. $3000, 7/01-6/02.

National Institutes of Health, PI Patrik Bavoil. NIH Subcontract Site **PI: AM \*\*\*\***. “Polymorphic Membrane Proteins of Chlamydia Trachomatis” $125,000 5/1/07-5/1/09.

National Institutes of Health Mentored Clinical Scientist Career Development Award (K08)- 1K08AI077932. **PI: AM \*\*\*\***. “Immunoregulatory Networks in Chlamydia Genital Tract Infection”. 12/25/2008-11/30/2013. Total Direct Costs: $612,500, Total Indirect Costs: $49,000, 75% Effort.

Food Allergy Research and Education (FARE), PI-S. Jones, **AM \*\*\*\***, “FARE Clinical Network.”

$300,000, 7/15-6/19. *\*transitioned to PI in 2017*

Food Allergy Research and Education (FARE), **PI: AM \*\*\*\*, “**FARE Clinical Network.” Discovery Center of Distinction, Food Allergy Collaborative of Texas and Arkansas. $100,000 annually, 9/2020- 8/2025

# Extramural Funding- Co-Investigator

Food Allergy and Anaphylaxis Network (FAAN). Co-PI: S. Jones, **Co-I:AM \*\*\*\***. “Oral Peanut Immunotherapy”, $81,250, 1/05-9/07.

NIH-NIAID, PI-H. Sampson, Site PI: S. Jones, **Co-I: AM \*\*\*\***. Consortium of Food Allergy Research, “Immunobiology of Peanut Allergy and Its Treatment: A Prototype Education Supplement”,

$245,955, 7/05-6/10.

National Peanut Board, Co-PI: S. Jones, AW Burks, **Co-I: AM \*\*\*\***. “Oral Immunotherapy for Peanut Allergy”, $300,000, 9/12/07-9/11/12.

Food Allergy Initiative and NIH, Site-PI: S. Jones, **Co-I: AM \*\*\*\***. “Establish a system for analyzing and certifying the quality of anti-allergy herbal products.” $172,231, 7/1/10-12/31/12.

Food Allergy Research and Education (FARE), Co-PI: S. Jones, AW Burks, **Co-I: AM \*\*\*\*** “Walnut Oral Immunotherapy (OIT) in Tree Nut Allergic Children and Adults”, $300,000, 3/1/12-12/31/17.

NIH-NIAID (U19AI066738), PI: H. Sampson, Site PI: S. Jones, **Co-I: AM \*\*\*\***. Consortium of Food Allergy Research, “Immunobiology of Peanut Allergy and Its Treatment: A Prototype”, $17,000,000 (Total Grant), $1,147,156 (Site Total), 7/05-6/10. Renewal (2U19AI066738): $1,389,311(Site Total) 7/10-6/17.

NIH-NIAID (UM1AI109565), PI: S. Jones (Study Co-Chair), **Co-I: AM \*\*\*\***. Immune Tolerance Network (ITN) “IMPACT Study: Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut Allergic Children.” $937,677, 5/1/12-9/30/19.

Food Allergy Research and Education (FARE), PI: S. Jones, **AM \*\*\*\***, “FARE Clinical Network.”$300,000, 7/15-6/19. *\*transitioned to PI in 2017*

NIH-NIAID (UM1AI130781) PI: S. Jones, **Co-I: AM \*\*\*\***. “Arkansas Center for Food Allergy Research (ArCOFAR)”. $1,645,000, 3/3/17-2/28/24.

NIH-NIAID (UM2AI130836) PI: R. Wood, Site PI: S. Jones, **Co-I: AM \*\*\*\***. “New Horizons in the Prevention and Treatment of Food Allergy.” 3/1/17-2/29/24: (Project 6, 7) $192,891, 3/1/17-8/31/18; (Project 11: OUtMATCH) $287,096/year, 3/1/19-2/29/23; (Project 12: SUNBEAM) $529,315/year, 9/1/18- 8/31/26 Role: Co-Investigator, Steering Committee, COI Committee

Johns Hopkins University, Project Director R. Wood, Site Project Director: S. Jones, **Co-I: AM \*\*\*\***. Funding agency, Genentech, Inc., “Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergy OIT in Food Allergic Children and Adults (OUtMATCH) COFAR 11 $235,146, 6/1/19 - 2/29/22.

NIH/NIAID (2U54AI117804-06) PI: M. Rothenberg, Site PI: RD Pesek, **Site Co-I-AM: \*\*\*\***. “A prospective, multicenter study to compare and validate endoscopic, histologic, molecular, and patient- reported outcomes in pediatric and adult patients with eosinophilic esophagitis, gastritis, and

colitis”. Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). $73,626. 9/17/2019- 8/31/2024.

NIH-NIAID (2UM1AI109565), Immune Tolerance Network, Co-PIs: J. Baker, R. Gruchalla, F. Adkinson; Site PI: S. Jones, **Co-I: AM \*\*\*\***. “Systemic Allergic Reactions to SARS-CoV-2 Vaccination”,

$585,150, 2/1/2021-1/31/2022.

# Intramural Funding- Principal Investigator

UAMS Arkansas Biosciences Institute Tobacco Settlement Research Fund. **PI: AM \*\*\*\*.** Immunopathogenesis of Chlamydia Genital Tract Infection. Support for salary and institutional research development funds. $344,703. 7/04-6/06.

Arkansas Children’s Hospital Research Institute (ACHRI) New Scientist Development Award. **PI: AM \*\*\*\***. “Persistence of *Chlamydia trachomatis* in the Female Gastrointestinal Tract”. $25,000. 9/05- 9/06.

UAMS Medical Research Endowment Herbert L. Thomas, Sr. Research Award. **PI: AM \*\*\*\***. “Characterization of Immunoregulatory Networks in Chlamydial Disease.” $13,947. 1/06-1/07.

Dean’s Research Development Fund. **PI: AM \*\*\*\***. “Immunoregulatory Networks in Chlamydial Disease.” $40,000. 1/06-1/08.

Marion B. Lyon New Scientist Development Award. **PI: AM \*\*\*\***. “The T-helper 17 Immune Response Following Chlamydia Trachomatis Genital Tract Infection” $50,000. 4/1/07-3/31/09.

Children’s University Medical Group, **PI: AM \*\*\*\***. Targeting PPAR-gamma to modulate the peanut allergic response. $40,000. 7/13-9/16.

# Clinical Trials

1. **Industry Funding-Principal Investigator**

Genocea Biosciences, **PI: AM \*\*\*\***. “T-cell Immune Responses to Chlamydia Trachomatis Infection”, $43,581, 8/1/08-7/31/2010.

Aimmune Therapeutics, Inc., **PI: AM \*\*\*\*.** Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years (RAMSES) (ARC007) $238,689, 07/01/2017-06/30/2019.

Aimmune Therapeutics, Inc., **PI: AM \*\*\*\***. A Multicenter, Open-label, Long-term Safety Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects who Participated in a Prior AR101 Study (ARC008) $244,289, 11/20/2017-11/20/2020.

Aimmune Therapeutics, Inc., **PI: AM \*\*\*\***. Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm Open-Label Extension Study (RAMSES OLE) (ARC011) $90,418, 02/01/2018-01/31/2020.

Aimmune Therapeutics, Inc., **PI: AM \*\*\*\***. Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON) (ARC005) $244,288, 10/01/2018-09/30/2021.

Aimmune Therapeutics, Inc. **PI: AM \*\*\*\***. Phase 2 Study of AR201 Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults with Hen Egg Allergy (AIME01) $138,653, 10/01/19-10/31/2021.

Siolta Therapeutics, **PI: AM \*\*\*\***. A Phase 1b/2, randomized, double-blind, placebo-controlled, multi-center study of STMC-103H in neonates and infants at high-risk for developing allergic disease.

$230,710, 6/1/2021-5/30/2023

Novartis, **PI: AM \*\*\*\*.** A 52-week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with peanut allergy. Study start-up in progress, Targeted FPFV 12/2021.

# Industry Funding- Co-Investigator

Novartis Pharmaceuticals Corporation, PI: S. Jones, **Co-I: AM \*\*\*\***. Xolair (Omalizumab), Protocol IA05, “A 1 Year, Randomized, Double Blind, Parallel-Group, Placebo-Controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Omalizumab in Children (6-<12 years) with Moderate-Severe, Persistent, Inadequately Controlled Allergic Asthma”, $72,784, 4/04-12/06.

Mead Johnson & Company, PI: S. Jones, **Co-I: AM \*\*\*\*.** “Assessment of Efficacy and Tolerance of Infant Formula Containing Prebiotics Fed to Infants”, $52,063, 4/04-4/05.

Aventis Pharmaceuticals, PI: S. Jones, **Co-I: AM \*\*\*\***, “A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, four-week Efficacy and Safety Evaluation of Nasacort AQ 110 µg QD, Followed by Six-Month Open-Label Safety in Children Ages 2-5 years with Perennial Allergic Rhinitis”, XRG5029C3502, $39,438, 5/04-3/06.

Genentech, PI: S. Jones, **Co-I: AM \*\*\*\***. “A Phase II, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Oral Food Challenge Trial of XOLAIR® (Omalizumab) in Peanut Allergy,”

$158,260, 6/04-6/05.

Mead Johnson & Company, PI: S. Jones, **Co-I: AM \*\*\*\***. “Double Blind Placebo Controlled Trial of an Amino Acid Formula vs. Neocate in Children with Milk Hypersensitivity”, $48,500, 6/04- 6/05.

Mead Johnson, PI: S. Jones, **Co-I: AM \*\*\*\***. “The Effects on Growth and Development on an Elemental Formula Fed to Term Infants”, $20,062.50, 9/04-9/05

Nestle, PI: S. Jones, **Co-I: AM \*\*\*\***. “Assessment of Growth of Infants Fed US Starter Formula Containing Synbiotics”, $104,687, 9/04-9/05

Dyax, Inc., PI: S. Jones, **Co-I: AM \*\*\*\***. “EDEMA2: Evaluation of DX-88’s Effects in Mitigating Angioedema. An Open Label Study to Access the Efficacy and Tolerability of Repeated Doses of DX-88 (recombinant plasma kallikrein inhibitor) in Patients with Hereditary Angioedema”, $17,387, 10/04-12/06.

Mead Johnson, PI: S Jones, **Co-I: AM \*\*\*\*,** “Double Blind Placebo Controlled Trial of an Amino Acid Formula vs. Neocate in Children with Milk Hypersensitivity”, $59,839, 5/05-4/07.

Dyax Corp., PI: S. Jones, **Co-I: AM \*\*\*\***, “Edema 3: Evaluation of Dx-88’s Effects in Mitigating Angioedema (A double-blind, placebo-controlled study followed by a repeat dosing phase to assess the efficacy and safety of Dx-88 for the treatment of acute attacks of Hereditary Angioedema)”,

$9,425, 1/5/06-1/5/07

Mead Johnson, PI: S. Jones, **Co-I: AM \*\*\*\*.** “The Effects of Growth and Tolerance of Hydrolyzed Formulas Fed to Term Infants”, $47,788, 5/06-5/07.

Dyax Corp., PI: S. Jones, **Co-I: AM \*\*\*\*,** “Edema 4: A Randomized, Double-Blind, Placebo- Controlled, Multi-Center Study to Assess the Efficacy and Safety of DX-88 (Ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema”, $38,650, 4/1/07-4/1/10.

Dyax Corp., PI: S. Jones, **Co-I: AM \*\*\*\*.** “DX88/19 “Open label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks”, $16,818, 4/1/07-4/1/10.

DBV Technologies, PI: S. Jones, **Co-I: AM \*\*\*\***. **“**Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Safety Study in Adult and Pediatric Subjects”, $358,875, 3/10-12/11.

Kedrion Biopharma, PI: R. Pesek, **Co-I: AM \*\*\*\***. “Multicenter, Open-label, historically controlled, Phase III Study to Assess the Efficacy, Tolerability, Safety, and Pharmacokinetics of Kedrion IVIG 10% in Adult and Pediatric Subjects with Primary Immunodeficiency (PID)”, $204,800, 4/13-6/14.

Danone Research, PI: R. Pesek, **Co-I: AM \*\*\*\***. “A prospective, double blind randomized controlled study to evaluate the immunological benefits and clinical effects of an elimination diet using an amino acid-based formula (AAF) with an added pre-probiotic blend in infants with cow’s milk allergy (PRESTO study).” $96,442, 2/1/13-7/30/19.

Allergen Research Corporation. PI: S. Jones, **Co-I: AM \*\*\*\***. “Oral Desensitization to Peanut in Peanut-Allergic Children and Adults using Characterized Peanut Allergen (CPNA) Oral Immunotherapy”,

$296,897, 1/1/14-12/31/14.

Allergen Research Corporation/Aimmune Therapeutics. PI: S. Jones, **Co-I: AM \*\*\*\***. “Oral Desensitization to Peanut in Peanut-Allergic Children and Adults using Characterized Peanut Allergen (CPNA) Peanut Oral Immunotherapy (OIT) Safety Follow-On Study”, $137,750, 5/14-10/17.

Patient Centered Outcomes Research Institute, PI: Pesek R, **Co-I: AM \*\*\*\***. Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs 4 Food Elimination Diet followed by Swallowed Glucocorticoids. $45,077, 1/1/15 – 12/31/17.

DBV Technologies, PI: S. Jones, **Co-I: AM \*\*\*\***. A Double-Blind, Placebo-Controlled Randomized Trial to Study the Efficacy and Safety of Viaskin Milk for Treating IgE-Mediated Cow’s Milk Allergy in Children (MILES Study)”, $131,330, 1/5/15-1/4/17.

Aimmune, Inc. PI: S. Jones, **Co-I: AM \*\*\*\***. “Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)”, $115,486, 12/2015-12/2017.

DBV Technologies, PI: S. Jones, **Co-I: AM \*\*\*\***. “A Double-Blind, Placebo-Controlled, Randomized Phase III Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy with Viaskin Peanut in Peanut-Allergic Children (PEPITES)”, $244,280, 5/2016-5/2018.

DBV Technologies, Inc., PI: S. Jones, **Co-I: AM \*\*\*\***. Long-term Assessment of Safety and Therapeutic Benefit of Viaskin Peanut Epicutaneous Treatment in Peanut-Allergic Children: A 6 month

Randomized, Double-blind, Placebo-Controlled Phase III Study Followed by An Open Label Active Treatment (REALISE Study). Phase 3, $241,665, 1/2017-1/2021.

DBV Technologies, Inc. PI: S. Jones, **Co-I: AM \*\*\*\***. Open Label Follow-up Study of the PEPITES Study to Evaluate the Long-Term Efficacy and Safety of Viaskin Peanut (PEOPLE STUDY) $124,400, 3/2017-2/2018.

DBV Technologies, PI: S. Jones, **Co-I: AM \*\*\*\***. A double-blind, placebo-controlled, randomized Phase 3 Trial to Assess the Safety and Efficacy of Viaskin® Peanut in Peanut- Allergic Young Children 1-3 Years of Age (EPITOPE) $159,791, 3/07/2017-2/28/2021.

Aimmune Therapeutics, Inc., PI: S. Jones, **Co-I: AM \*\*\*\***. Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow on Study (ARC004)

$140,856, 03/17/2017-02/28/2020.

Astellas Pharma, Inc. PI: S. Jones, **Co-I: AM \*\*\*\***. Phase 1, Randomized, Placebo Controlled Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut after Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA LAMP vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmin Vaccine MATRIX 1001,

$219,698. 8/2017-2/2019.

DBV Technologies, PI: TT Perry, **Co-I: AM \*\*\*\***. An open-label Phase I study to assess the biological potency of peanut allergens extract in adolescent and adult peanut allergic subjects (BIOPOT study) $97,379, 01/31/2018-12/31/2018.

Regeneron Pharmaceuticals, Inc. PI: RD Pesek, **Co-I: AM \*\*\*\***. A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab In Adult and Adolescent Patients with Eosinophilic Esophagitis (EOE) $65,037, 11/01/2018-10/31/2023.

Astellas Pharma, Inc. PI: S. Jones, **Co-I: AM \*\*\*\*.** Phase 1, Randomized, Placebo Controlled Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut after Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA LAMP vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmin Vaccine MATRIX 1002, $162,550. 11/2018-2/2021

DBV Technologies, PI: S. Jones, **Co-I: AM \*\*\*\***. EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children (EPOPEX)

$183,587, 12/01/2018-12/31/2021.

Regeneron Pharmaceuticals, Inc. PI: S. Jones, **Co-I: AM \*\*\*\*.** A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Subjects with Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101-CODIT (Peanut Oral Immunotherapy (OIT) $266,788, 2/01/18-6/30/2021.

Regeneron Pharmaceuticals, Inc.; PI: RD Pesek, **Co-I: AM \*\*\*\***. A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis, $221,916, 11/2019-12/2021.

Regeneron Pharmaceuticals, Inc.; PI: RD Pesek, **Co-I: AM \*\*\*\***. A Randomized, Double-blind, placebo-controlled Study to investigate the Efficacy and Safety of Dupilumab in Pediatric Patients with Active Eosinophilic Esophagitis, $205,102. 7/20-7/22.

AstraZeneca AB; PI: RD Pesek, **Co-I: AM \*\*\*\***. A Multi-center, Randomized, Double-blind, parallel- group, placebo-controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA), $244,168, 8/20-8/22.

# Pending submissions:

NIAID U44 Fast-track Application, Moonlight Therapeutics, PI: Samirkumar Patel, **Co-I: AM \*\*\*\***. “Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy.” *In review*.

NIAID U01 Implementation Award, Siolta Therapeutics, **Site PI: AM \*\*\*\***. A Phase 2 randomized, double-blind, placebo-controlled trial of STMC-103H to prevent food allergy in infants with atopic dermatitis. *In review.*

# Publications

Dr. \*\*\*\* has authored 44 peer-reviewed full-length original manuscripts, 10 invited review articles, and five book chapters, including being lead author for the book chapter in Pediatric Allergy, a leading textbook for the field, on immunotherapy for treatment of food allergy. She has four manuscripts that are currently in preparation or in review, including collaboration with experts in the field and innovative leaders in industry.

# Peer-reviewed original articles

* 1. **\*\*\*\* AM**, Althage KA, Christie L, Burks AW, Jones SM. Anaphylaxis after ingestion of gummy bears. *J Allergy Clin Immunol* 2002 Dec;110(6):936-7. PMID: 12464963
	2. Rosenzweig SD, Dorman SE, Uzel G, Shaw S, **\*\*\*\* AM**, Brown MR, Buckley RH, Holland SM. A novel mutation in Interferon-gamma receptor 2 with dominant negative activity: biological consequences of homozygous and heterozygous states*. J Immunol*. 2004 Sep 15; 173(6): 4000- 4008. PMID: 15356149
	3. Buchanan AD, Green TD, Jones SM, **\*\*\*\* AM**, Christie L, Althage KA, Steele PH, Pons L, Helm RM, Lee LA, Burks AW. Egg oral immunotherapy in nonanaphylactic children with egg allergy. *J Allergy Clin Immunol*. 2007 Jan;119 (1): 199-205. PMID: 17208602
	4. O’Connell CM, Ingalls R, Andrews CW, **\*\*\*\* AM**, Darville T. Plasmid-deficient *Chlamydia muridarum* fail to induce immune pathology and protect against oviduct disease. *J. Immunol*. 2007 Sep 15;179(6):4027-34. PMID: 17785841
	5. Hofmann AM, **\*\*\*\* AM**, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, Kamilaris J, Burks AW. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. *J Allergy Clin Immunol*. 2009 Aug; 124(2): 286-91, 291.e1-6. PMID 19477496.
	6. Tan C, Hsia RC, Shou H, Haggerty CL, Ness RB, Gaydos CA, Dean D, **\*\*\*\* AM**, Wilson DP, Bavoil PM. Chlamydia trachomatis-infected patients display variable antibody profiles against the nine-member polymorphic membrane protein family. *Infect Immun*. 2009 Aug; 77(8): 3218-26. PMID: 19487469.
	7. Jones SM, Pons L, Roberts JL, **\*\*\*\* AM**, Perry TT, Kulis M, Shreffler WG, Steele P, Henry KA, Adair M, Francis JM, Durham S, Vickery BP, Zhong X, Burks AW. Clinical efficacy and immune regulation with peanut oral immunotherapy. *J Allergy Clin Immunol*. 2009 Aug;124:292-300.e1-97. PMID 195777283.
	8. Varshney P, Steel PH, Vickery BP, Bird JA, Thyagarajan A, **\*\*\*\* AM**, Perry TT, Jones SM, Burks AW. Adverse reactions during peanut oral immunotherapy home dosing. *J Allergy Clin Immunol* 2009 Dec;124(6):1351-1352. PMID: 19913285
	9. Chavez A, Mian A, **\*\*\*\* AM**, Blackall D, Com G. Antibiotic hypersensitivity in CF: Drug-induced life-threatening hemolytic anemia in a pediatric patient. *J. Cystic Fibrosis* 2010 Dec; 9(6): 433-438. PMID: 20833594
	10. **\*\*\*\* AM**, Frazer LC, Andrews CW Jr., O’Connell CM, Foote IP, Bailey SL, Chandra-Kuntal K, Kolls JK, Darville T. IL-17 contributes to generation of Th1 immunity and neutrophil recruitment during *Chlamydia muridarum* genital tract infection but is not required for macrophage influx or normal resolution of infection. *Infect. Immun*. 2011 Mar; 79(3):1349-1362. PMID: 21149587
	11. O’Connell CM, Abdelrahman YM, Green E, Darville HK, Saira K, Smith B, Darville T, **\*\*\*\* AM**, Meyer CR, Belland RJ. Toll-like receptor 2 activation by *Chlamydia trachomatis* is plasmid- dependent and plasmid-responsive chromosomal loci are coordinately regulated in response to glucose limitation by *C. trachomatis* but not by *C. muridarum Infect. Immun.* 2011 Mar; 79(3):1044- 1056. PMID: 21199910
	12. Varshney P, Jones SM, **\*\*\*\* AM**, Perry TT, Kemper A, Steele P, Hiegel A. Kamilaris J, Carlisle S, Yue X, Kulis M, Pons L, Vickery B. Burks AW. A randomized controlled study of peanut oral immunotherapy (OIT): clinical desensitization and modulation of the allergic response. *J Allergy Clin Immunol* 2011 Mar; 127(3): 654-60. PMID: 21377034.
	13. Lacy HM, Bowlin AK, Hennings L, **\*\*\*\* AM**, Nagarajan UM, Rank RG. Essential role for neutrophils in pathogenesis and adaptive immunity in *Chlamydia caviae* ocular infections. *Infect Immun* 2011 May; 79(5): 1889-97. PMID: 21402767.
	14. Anvari S, **\*\*\*\* AM**, Hall PH, Jones SM, Perry TT. Influenza vaccination can be safely administered to most egg-allergic patients. *J Ark Med Soc* 2011 Nov; 108(6): 103-4. PMID: 23252020
	15. Woods JL, Bailey SL, Hensel DJ, **\*\*\*\* AM**. Cervicitis in Adolescents: Do We Really Understand Diagnosis and Treatment? *J Pediatr Adolesc Gynecol.* 2011 Dec; 24(6): 359-364. Epub 2011 Aug 27. PMID: 21872515.
	16. Burks, AW\*, Jones SM\* (\*Co-first authors), Wood RA, Fleischer DM, Sicherer SH, Lindblad D, Stablein D, Henning AK, Vickery BP, Liu AH, **\*\*\*\* AM**, Shreffler WG, Plaut M, Sampson HA, for the Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. *New Engl J Med* 2012 Jul; 367(3): 233-243. PMID: 22808958
	17. Thyagarajan A, Jones SM, Calatroni A, Pons L, Kulis M, Woo CS, Kamalakannan M, Vickery BP, **\*\*\*\* AM**, Burks AW, Shreffler WG. Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children. *Clin Exp Allergy* 2012 Aug; 42(8);1197-1205. PMID: 22805467
	18. Bell MC, Stovall SH, **\*\*\*\* AM**, Perry TT, Jones SM, Harik NS. Addressing antimicrobial resistance to treat children with atopic dermatitis in a tertiary pediatric allergy clinic. *Clin Pediatr* 2012 Nov; 51(11):1025-1029. PMID: 22514191
	19. Fleischer DM, Burks AW, Vickery BP, **\*\*\*\* AM**, Wood RA, Jones SM, Sicherer SH, Liu AH, Stablein D, Henning AK, Mayer L, Lindblad R, Plaut M, Sampson HA; Consortium of Food Allergy Research (CoFAR). Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo-controlled multicenter trial. *J Allergy Clin Immunol* 2013 Jan; 131(1):119-127. e 1-7. PMID: 23265698
	20. Vickery BP, Lin J, Kulis M, Fu Z, Steele PH, Jones SM, **\*\*\*\* AM**, Gimenez G, Bardina L, Sampson HA, Burks AW. Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens. *J Allergy Clin Immunol* 2013 Jan; 131(1): 128-134.e1-3. PMID: 23199605
	21. Small TN, Qasim W, Friedrich W, Chisea R, Bleesing JJ, **\*\*\*\* AM**, Veys P, Sparber-Sauer M. Alternative donor SCT for the treatment of MHC class II deficiency. *Bone Marrow Transplant.* 2013 Feb; 48(2): 226-32. PMID: 23000650
	22. Chin SJ, Vickery BP, Kulis MD, Kim EH, Varshney P, Steele P, Kamilaris J, Hiegel AM, Carlisle SK, Smith PB, **\*\*\*\* AM**, Jones SM, Burks AW. Sublingual versus oral immunotherapy for peanut- allergic children: A retrospective comparison. *J Allergy Clin Immunol.* 2013; Epub 2013 March 24. 2013 Aug; 132(2): 476-478. e.2. PMID: 23534975
	23. Woods JL, **\*\*\*\* AM**, Hensel DJ. Pelvic inflammatory disease in the adolescent: understanding diagnosis and treatment as a health care provider. *Pediatr Emerg Care*. 2013 Jun; 29 (6): 720-725. PMID: 23714759
	24. Petitto J, Chervinskiy S, **\*\*\*\* AM**, Perry TT, Jones SM, Pesek RD. Successful clarithromycin desensitization in a macrolide-sensitive, pediatric patient. *J Allergy Clin Immunol: In Practice* 2013 2013 May-June; 1(3): 307-308. PMID: 24565493
	25. Kennedy JL, Jones SM, Porter N, White ML, Gephardt G, Hill T, Cantrell M, Boateng BA, Perry TT, **\*\*\*\* AM**, Thompson TM. High fidelity hybrid simulation of allergic emergencies demonstrates improved preparedness for office emergencies in pediatric allergy clinics. *J Allergy Clin Immunol: In Practice* 2013 Nov-Dec; 1(6): 608-617.e14. PMID: 24565708
	26. Dilley MA, Jones SM, Perry TT, **\*\*\*\* AM**, Brodie-Fowler M, Bufford JD, Pesek RD. Pneumococcal meningitis in a patient with IL-1 receptor associated kinase-4 deficiency: A case of failed prophylaxis. *J Allergy Clin Immunol Pract* 2013 Nov-Dec; 1(6); 700-3. PMID: 24565725
	27. Frazer LC, **\*\*\*\* AM**, Zurenski MA, Riley MM, Mintus M, Pociask DA, Sullivan JE, Andrews CW, Darville T. IL-23 induces IL-22 and IL-17 production in response to *Chlamydia muridarum* genital tract infection, but the absence of these cytokines does not influence disease pathogenesis*. Am J Reprod Immunol*. 2013 Dec; 70(6): 472-484. PMID: 24238108
	28. Vickery BP, **\*\*\*\* AM**, Kulis M, Steele PH, Kamilaris J, Berglund JP, Burk C, Hiegel A, Carlisle S, Christie L, Perry TT, Pesek RD, Sheikh S, Virkud Y, Smith PB, Shamji MH, Durham SR, Jones SM, Burks AW. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. *J Allergy Clin Immunol*. 2014 Feb; 133(2): 468-475.e.6. PMID: 24361082. PMCID: PMC3960331
	29. Burks WA, Wood RA, Jones SM, Sicherer SH, Fleischer DM, **\*\*\*\* AM**, Vickery BP, Liu AH, Henning AK, Lindblad R, Dawson P, Marshall P, Sampson HA. Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial. *J Allergy Clin Immunol* 2015 May; 135(5):1240-8, e1-3. PMID: 25656999
	30. Song Y, Wang J, Leung N, Lisann L, Wang L, Ross J, Sicherer SH, **\*\*\*\*, AM**, Pesek R, Perry TT, Jones SM, Li, XM. Correlations between basophil activation, specific IgE, and skin test wheal size with outcome and severity of oral food challenges. *Ann Allergy Asthma Immunol.* 2015:114:319- 26. PMID: 25841330
	31. Jones SM, Burks AW, Keet C, Vickery BP, \*\*\*\* AM, Wood RA, Liu AH, Sicherer SH, Henning AK, Lindblad RW, Dawson P, Berin C, Fleischer DM, Leung DY, Plaut M, Sampson HA; Consortium of Food Allergy Research (CoFAR). Long-term treatment with egg oral immunotherapy enhances

sustained unresponsiveness that persists after cessation of therapy. J Allergy Clin Immunol. 2016 Apr; 137(4): 1117-1127. PMID: 26924470

* 1. Virkud YV, Burks AW, Steele PH, Edwards L, Berglund JP, Jones SM, **\*\*\*\* AM**, Perry TT, Pesek R, Vickery BP. Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol 2017 Mar; 139(3):882-888. PMID: 27609653
	2. Pesek RD, Rettiganti M, O’Brien E, Beckwith S, Daniel C, Luo C, **\*\*\*\* AM**, Chandler P, Levy RA, Perry TT, Kennedy JL, Chervinskiy S, Vonlanthen M, Casteel H, Fiedorek S, Gibbons T, Jones SM. Effects of allergen sensitization on response to therapy in children with eosinophilic esophagitis. Ann Allergy Asthma Immunol 2017 Aug;119(2):177-183. PMID: 28676207
	3. Cranmer JM, **\*\*\*\* AM**, Hale RB, Ward WL, Prodhan P, Weber JL, Casey PH, Jacobs RF. An Adaptable Pediatrics Faculty Mentoring Model. Pediatrics. 2018 May;141(5). pii: e20173202. doi: 10.1542/peds.2017-3202. PMID: 29669752.
	4. Chiang SCC, Vergamini SM, Husami A, Neumeier L, Quinn K, Ellerhorst T, Sheppard L, Gifford C, Buchbinder D, Joshi A, Ifversen M, Kleiner GI, Bussel JB, Chandrakasan S, Pesek RD, Pozos TC, Rose MJ, **\*\*\*\* AM**, Zhang K, Bryceson YT, Bleesing J, Marsh RA. Screening for Wiskott- Aldrich Syndrome by flow cytometry. J Allergy Clin Immunol. 2018 Jul;142(1):333-335.e8. PMID: 29729304
	5. Poston TB, O’Connell CM, Girardi J, Sullivan JE, Nagarajan UM, Marinov A, **\*\*\*\* AM**, Darville

T. T-cell-Independent gamma interferon and B-cells cooperate to prevent mortality associated with disseminated Chlamydia muridarum genital tract infection. Infect Immun. 2018 Jun 21: 86(7): e00143-18. PMID: 29661927

* 1. Dilley MA, Rettiganti M, Christie L, O'Brien E, Patterson M, Weeks C, Aronson J, **\*\*\*\* AM**, Perry TT, Pesek RD, Bell MC, Kennedy JL, Chandler P, Magee J, Simmons L, Chervinskiy SK, Casey P, Jones SM. Impact of food allergy on food insecurity and health literacy in a tertiary care pediatric allergy population. Pediatr Allergy Immunol. 2019 May;30(3):363-369. doi: 10.1111/pai.13019. Epub 2019 Mar 1. PMID: 30672621
	2. Do AN, Watson CT, Cohain AT, Griffin RS, Grishin A, Wood RA, Wesley Burks A, Jones SM, **\*\*\*\* AM**, Leung DYM, Sampson HA, Sicherer SH, Sharp AJ, Schadt EE, Bunyavanich S. Dual transcriptomic and epigenomic study of reaction severity in peanut-allergic children. J Allergy Clin Immunol. 2020 Apr;145(4):1219-1230. Epub 2019 Dec 12. PMID: 31838046
	3. Kim EH, Jones SM, Burks AW, Wood RA, Sicherer SH, Leung DYM, Henning AK, Lindblad RW, Dawson P, Keet C, **\*\*\*\* AM**, Plaut M, Sampson HA. A 5-year summary of real-life dietary egg consumption after completion of a 4-year egg powder oral immunotherapy (eOIT) protocol. J Allergy Clin Immunol. 2020 Apr;145(4):1292-1295.e1. Epub 2019 Dec 24. PMID: 31881232
	4. Kim EH, Perry TT, Wood RA, Leung DYM, Berin MC, Burks AW, Cho CB, Jones SM, **\*\*\*\* AM,** Sicherer SH, Henning AK, Dawson P, Lindblad RW, Plaut M, Sampson HA; Consortium for Food Allergy Research (CoFAR). Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy. J Allergy Clin Immunol. 2020 Oct;146(4):851-862. PMID: 32535135
	5. Fleischer DM, Chinthrajah S, **\*\*\*\* AM**, Campbell DE, Green TD, Bee KJ, Peillon A, Ocheltree T, Sampson HA. An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial. Allergy Asthma Proc. 2020 Sep 1;41(5):326-335. PMID: 32539908.
	6. **\*\*\*\* AM**, Burks AW, Sicherer SH, Leung DYM, Kim EH, Henning AK, Dawson P, Lindblad RW, Berin MC, Cho CB, Davidson WF, Plaut M, Sampson HA, Wood RA, Jones SM. Epicutaneous Immunotherapy for Treatment of Peanut Allergy: Follow-up from the Consortium for Food Allergy Research. J Allergy Clin Immunol. 2020 Dec 5; PubMed PMID: 33290772. *\*\*JACI/AAAAI Featured Publication*
	7. Aluri J, Bach A, Kaviany S, Chiquetto-Paracatu L, Kitcharoensakkul M, Walkiewicz MA, Putnam CD, Shinawi M, Saucier N, Rizzi EM, Harmon MT, Keppel MP, Ritter M, Similuk MN, Kulm E, Joyce M, Almeida de Jesus A, Goldbach-Mansky R, Lee Y, Cella M, Kendall PL, Dinauer MC, Bednarski JJ, Bemrich-Stolz C, Canna S, Abraham S, Demczko MM, Powell J, Jones SM, **\*\*\*\* AM**, De Ravin SS, Bleesing J, Connelly JA, Rao VK, Laura Schuettpelz L, Cooper MA. Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain-of-function. Blood 2021, May 6;137(18):2450- 2462. PMID: 33512449 PMCID: PMC8109013*.*
	8. Nilsson C, **\*\*\*\* AM**, Dellon ES, Brostoff JM, Pham T, Ryan R, Brown KR, Adelman DC, Aceves SS. Onset of Eosinophilic Esophagitis During a Clinical Trial Program of Oral Immunotherapy for Peanut Allergy. J Allergy Clin Immunol Pract. 2021 Aug 11:S2213-2198. PMID: 34389504
	9. Berin MC, Agashe C, Burks AW, Chiang D, Davidson W, Dawson P, Grishin A, Henning A, Jones SM, 5, Kim E, Leung D, Masilamani M, **\*\*\*\* AM**, Sicherer SH, Wood RA, Sampson HA. Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts. *Accepted for publication, J Allergy Clin Immunol.*, September 17, 2021.
	10. Pongracic JA, Gagnon R, Sussman G, Siri D, Oriel RC, Brown-Whitehorn T, Green TD, Campbell DE, Anvari S, Berger WE, Bird JA, Chan ES, Cheema A, Chinthrajah S, Chong H, Dowling PJ, Fineman SM, Fleischer DM, Gonzalez-Reyes E, Kim EH, Lanser BJ, MacGinnitie A, Mehta H, Petroni D, Rupp N, Schneider LC, **\*\*\*\* AM**, Sher LD, Shreffler WG, Sindher SB, Stillerman A, Wood RA, Yang WH, Bois T, Sampson HA, Begin P. Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results. *In review, submitted to J. Allergy Clin Immunol Pract.*
	11. Jones SM, MD, Kim EH, Nadeau KC, Nowak-Wegrzyn A, Wood RA, Sampson HA, **\*\*\*\* AM**, Chinthrajah S, Wang J, Pesek RD, Sindher SB, Kulis M, Johnson J, Spain K, Babineau DC, Chin H, Laurienzo-Panza J, Yan R, Larson D, Qin T, Whitehouse D, Sever ML, Sanda S, Plaut M, Wheatley LM, and Burks AW, for the Immune Tolerance Network. Efficacy and Safety of Oral Immunotherapy in a Randomized, Placebo-Controlled Study of 1-3-Year Old Children with Peanut Allergy: Findings from the Immune Tolerance Network IMPACT Trial. *In review, submitted to The Lancet.*
	12. **\*\*\*\* AM**, Rettiganti MR, Hiegel AM, Sood A, House SE, Chervinskiy SK, Pesek RD, Perry TT, Kennedy JL, Chandler P, Burks AW, Jones SM. Long-term Walnut Oral Immunotherapy Induces Clinically Relevant Treatment Responses in Tree Nut Allergic Children. *In preparation.*
	13. Price AS, Rogers AL, Seminara EJ, Jin J, Murphy C, Sood A, Munoz-Mendoza D, Manegold E, Whitaker BN, Roberson P, Parrish C Jones SM, Bird JA, **\*\*\*\* AM**. Assessment of Anxiety, Depression and Resilience in Food-Allergic Adolescents and Primary Caregivers in Two Food Allergy Centers During the COVID-19 Pandemic. *In preparation.*

# Review Articles/Editorials/Book Chapters

* 1. **\*\*\*\* AM**, Burks AW. Peanut allergenicity. *Ann Allergy Asthma Immunol*. 2004 Nov; 93(5 suppl 3): S12-18. PMID: 15562869
	2. **\*\*\*\* AM**, Burks AW. Food Allergy. In: *Atlas of Allergy and Clinical Immunology, Third Edition*. Fireman P.(ed.). Elsevier, Philadelphia, 2004.
	3. **\*\*\*\* AM**, Lee LA, Burks AW. Food allergy in children. *Immunol Allergy Clin North Am*. 2005 May; 25(2): 369-88. PMID: 15878461
	4. Perry TT, **\*\*\*\* AM**, Jones SM. Clinical Manifestations of food allergic disease. In: *Food Allergy: Comprehension, Treatment, and Prevention*. Maleki, Helm, Burks (eds.) ASM Press, 2006.
	5. Jones SM, **\*\*\*\* AM**. The impact of food allergy: the real “fear factor”. *Ann Allergy Asthma Immunol*. 2006 Mar; 96(3): 385-6. PMID: 16597070
	6. **\*\*\*\* AM**, Burks AW, Jones SM. Oral Immunotherapy for Food Allergy. *Curr Allergy Asthma Rep*. 2009 May; 9(3): 186-93. PMID:19348718
	7. **\*\*\*\* AM**, Vickery BP, Hourihane JO’B, Burks AW. Pediatric Food Allergy and Mucosal Tolerance. *Mucosal Immunol*. 2010 Jul;3(4):345-54. PMID: 20505663.
	8. **\*\*\*\* AM**, Jones SM. An update on immunotherapy for food allergy. *Curr Opin All Clin Immunol* 2010 Dec; 10(6): 587-593. PMID: 20856110.
	9. Vickery BP, **\*\*\*\* AM**, Jones SM, Burks AW. Mechanisms of immune tolerance relevant to food allergy. *J Allergy Clin Immunol.* 2011 Mar; 127(3):576-584. PMID: 21277624.
	10. Pesek R.D., **\*\*\*\* A.M**., Jones S.M. (2014) Food Allergy and its Future Treatment. In: Mackay I.R., Rose N.R., Ledford D.K., Lockey R.F. (eds) Encyclopedia of Medical Immunology. Springer, New York, NY
	11. **\*\*\*\* AM**. (2014) Food Allergies, Diagnostic Testing. In: Mackay I.R., Rose N.R., Ledford D.K., Lockey R.F. (eds) Encyclopedia of Medical Immunology. Springer, New York, NY
	12. **\*\*\*\* AM**. Oral and Sublingual Immunotherapy for Treatment of IgE-Mediated Food Allergy. Clin Rev Allergy Immunol. 2018 Oct;55(2):139-152. doi: 10.1007/s12016-018-8677-0. PMID : 29656306
	13. **\*\*\*\* AM**, Jones SM. Advances in the approach to the patient with food allergy. J Allergy Clin Immunol. 2018 Jun;141(6):2002-2014. doi: 10.1016/j.jaci.2017.12.1008. Epub 2018 Mar 8. PMID: 29524535
	14. **\*\*\*\* AM**, Shreffler WG. Immunotherapeutic Approaches to the Treatment of Food Allergy. In: Sampson HA, Leung DYM (eds) Pediatric Allergy, 4th Edition. Elsevier, 2020.
	15. Sood AK, **\*\*\*\* AM.** Food Allergy Primer 2020: Food Allergy Oral Immunotherapy. J Food Allergy 2 (1):75-80.

# Newsletter/Community Education:

* 1. **\*\*\*\* AM,** Burks AW. Food Allergy in Adults. *Food Allergy and Anaphylaxis Network Food Allergy News.* December 2004- January 2005.
	2. **\*\*\*\* AM.** Newborn screening for Severe Combined Immunodeficiency. Arkansas Department of Health Nursing Follow-Up Letter. July 2013.

# Abstracts and Presentations (oral or poster presentations): National/International Meetings:

* 1. **\*\*\*\* AM**, Bhutta AT, Heulitt MJ, Harville TO, Burks AW, Jones SM. Near-Fatal Pneumocystis Carinii pneumonia in a previously immunocompetent infant treated with high-dose corticosteroids. *J Allergy Clin Immunol*, 2001;107:S212.

2.

**\*\*\*\* AM**, Althage KA, Christie L, Burks AW, Jones SM. Anaphylaxis Following Ingestion of Gummi Bears. *J Allergy Clin Immunol;* 2002.

1. **\*\*\*\* AM**, Vargas PA, Field CR, Wheeler JG, Simpson PM, Barrett KW, Flick EL, Jones SM. Asthma knowledge among Head Start staff. *Am J Resp Crit Care Med*; 2002.
2. **\*\*\*\* AM**, Shaw SG, Rosenzweig SD, Sajaroff EO, Holland SM, Buckley RH. Interferon- Receptor-2 Deficiency Presenting with Cytomegalovirus Infection. *J Allergy Clin Immunol;* 2003.
3. Fuhrman SC, **\*\*\*\* AM**, Peloquin CA. Intravenous Moxifloxacin Pharmacokinetics in an Immunocompromised Infant with Disseminated Mycobacterium Avium Complex Infection*. Pediatric Pharmacy Advocacy Group (PPAG);* October 2003.
4. **\*\*\*\* AM**, Rosenzweig SD, Sajaroff EO, Martin PL, Holland SM, Buckley RH. Successful HLA-Identical Bone Marrow Transplantation in a Patient with Interferon- Receptor 2 Deficiency and Disseminated *Mycobacterium avium* Complex Infection. *J Allergy Clin Immunol*; 2004.
5. **\*\*\*\* AM,** Steele PH, Andrzejewski SS, Pons LA, Althage KA, Christie L, Carlisle SK, Buchanan AD, Jones SM, Burks AW. Safety of Oral Peanut Immunotherapy for Peanut Allergic Patients. *J Allergy Clin Immunol* 2005; S246.
6. Christie L, Althage KA, Burks AW, **\*\*\*\* AM**, Perry TT, Buchanan AD, Helm RM, Pons LA, Andrzejewski SS, Steele PH, Jones SM. Threshold Dose for Egg Allergy During Egg Desensitization Procedure. *J Allergy Clin Immunol* 2005; S168.
7. Buchanan AD, Jones SM, Christie L, Althage KA, **\*\*\*\* AM,** Helm RM, Pons LA, Andrzejewski SS, Steele PH, Burks AW. Treatment of Egg Allergy in Children Through Oral Desensitization. *J Allergy Clin Immunol* 2005; S167.
8. Buchanan AD, **\*\*\*\* AM**, Jones SM, Christie L, Althage KM, Pons LA, Steele PH, Burks AW. Oral Desensitization and Induction of Tolerance in Peanut-Allergic Children. *J Allergy Clin Immunol* 2006; S327.
9. LeBras MH, Saccente SL, Saylors RL, Perry TT, Jones SM, **\*\*\*\* AM**. Modified Desensitization Protocol Using Two Formulations of L-Aspariginase in a Pediatric Patient with Recurrent Acute Lymphoblastic Leukemia (ALL). *J Allergy Clin Immunol* 2006; S230.
10. Bailey AE, Bleesing JJH, Jones SM, Perry TT, Nagarajan UM, **\*\*\*\* AM**. Major Histocompatibility Complex Class II Deficiency in a Child with Panhypogammaglobulinemia and Lymphopenia. *J Allergy Clin Immunol* 2007; 119 (1):S255.
11. **\*\*\*\* AM**, Jones SM, Burks AW. Oral Peanut Immunotherapy for Peanut Allergic Patients.

*J Allergy Clin Immunol* 2007;119(1):S158.

1. Nash, SD, Steele PH, Kamilaris JS, Pons LA, Kulis M, Lee LA, Althage KM, Christie L, **\*\*\*\* AM**, Jones SM, Burks AW. Oral Peanut Immunotherapy for Peanut Allergic Patients. *J Allergy Clin Immunol* 2007;119(1):S158.
2. **\*\*\*\* AM**, Sikes JD, Foote IP, Rank RG, Darville T. Regulatory T-lymphocyte Kinetics Following Genital Tract Infection with Chlamydia Muridarum. Chlamydia Basic Research Society Meeting March 2007.
3. Adair MA, Laubach SS, Steele P, Kamilaris J, Pons L, Kulis M, **\*\*\*\* AM**, Jones SM, Burks AW. Mean wheal size from peanut prick skin test and IgE levels in peanut allergic patients receiving oral peanut immunotherapy. *J Allergy Clin Immunol* 2008;121(2):S136.
4. Hofmann AM, Steele P, Kamilaris JS, Jones SM, Palmer KP, Perry TT, **\*\*\*\* AM**, Althage KA, Burks AW. Safety of Peanut Oral Immunotherapy (OIT). *J Allergy Clin Immunol* 2008;121(2):S137.
5. Nash SD, Steele PH, Kamilaris JS, Pons L, Kulis MD, Lee LA, **\*\*\*\* AM**, Palmer KP, Perry TT, Jones SM, Burks AW. Oral peanut immunotherapy for children with peanut allergy. *J Allergy Clin Immunol* 2008;121(2):S136.
6. Chavez A, Mian A, **\*\*\*\* AM**, Com G. Piperacillin-induced, Life-threatening Hemolytic Anemia in a Patient with Cystic Fibrosis. Presented at the Fellows’ Complicated Case Conference at the North American Cystic Fibrosis Conference (NACFC), Orlando, FL, October 2008.
7. **\*\*\*\* AM,** Andrews CW, O’Connell CM, Foote IP, Chandra-Kuntal K, Darville T. Genital Mucosal T-helper 17 Responses in Chlamydia Infection and Immunopathogenesis. Presented at Keystone Symposium “T-helper 17 Cells in Health and Disease”, February 5-9, 2009, Vancouver, B.C.
8. Christie L, Althage KA, **\*\*\*\* AM**, Perry TT, Pons L, Steele P, Kamilaris J, Jones SM**,** Burks AW. Threshold dose for peanut allergy during peanut oral immunotherapy procedure in children. *J Allergy Clin Immunol* 2009;123(2):284.
9. Perry TT, **\*\*\*\* AM**, Jones SM, Tilford JM. Economic and caregiver impacts of food allergy (FA): Analyses from the 2005-2006 National Survey of Children with Special Health Care Needs. *J Allergy Clin Immunol* 2009;123(2):428.
10. Bird JA, **\*\*\*\* AM**, Perry TT, Jones SM, Pons LA, Kulis MD, Burks AW. Regulatory T-cell patterns and cytokine profiles suggest the development of tolerance in patients undergoing peanut oral immunotherapy (OIT). *J Allergy Clin Immunol* 2009;123(2):576.
11. Jones SM, **\*\*\*\* AM**, Pons L, Kulis M, Perry TT, Steele P, Kamilaris J, Henry KA, Burks AW. Double-blind, placebo-controlled (DBPC) trial of oral immunotherapy (OIT) in peanut allergic children. *J Allergy Clin Immunol* 2009;123(2):814.
12. Varshney P, Jones SM, Pons L, Kulis M, Steele PH, Kemper AR, **\*\*\*\* AM**, Perry TT, Burks AW. Oral immunotherapy (OIT) induces clinical tolerance in peanut-allergic children. *J Allergy Clin Immunol* 2009;123(2):665.
13. Pesek RD, Vargas PA, Jones SM, **\*\*\*\* AM**, McCracken A, Perry TT. Asthma prevalence and morbidity among urban and rural school children in Arkansas. *J Allergy Clin Immunol* 2009;123(2):808.
14. Kennedy JL, Thompson TM, Perry TT, **\*\*\*\* AM**, Jones SM. Medical training in common pediatric allergic emergencies using high fidelity patient simulation mannequins. *J Allergy Clin Immunol* 2009;123(2):173-A.
15. Varshney P, Jones SM, Pons L, Kulis M, Steele PH, Kemper AR, **\*\*\*\* AM**, Perry TT, Burks AW. Oral immunotherapy (OIT) induces clinical tolerance in peanut-allergic children. *J Allergy Clin Immunol* 2009;123(2):665.
16. **\*\*\*\* AM,** Andrews CW, O’Connell CM, Foote IP, Chandra-Kuntal K, Darville T. Genital Mucosal T-helper 17 Responses in Chlamydia Infection and Immunopathogenesis. Keystone Symposium “T-helper 17 Cells in Health and Disease”, February 7, 2009, Vancouver, B.C.
17. **\*\*\*\* AM**, O’Connell CM, Andrews CW, Foote IP, Darville T. Mucosal T-helper 17 Responses to *Chlamydia* Genital Tract Infection. Oral Presentation at American Academy of Allergy, Asthma, and Immunology Meeting, March 15, 2009, Washington, D.C. *J Allergy Clin Immunol* 2009;123(2):526.
18. **\*\*\*\* AM**, O’Connell CM, Andrews CW, Foote IP, Chandra-Kuntal K, Darville T. T-helper 17 Responses following *Chlamydia muridarum* Genital Tract Infection. Presented at the Chlamydia Basic Research Society Meeting, March 21-23, 2009.
19. Darville T, Chandra-Kuntal K, Frazer L, **\*\*\*\* AM**, O’Connell CM. Lack of oviduct pathology in mice infected with TLR2-signaling deficient chlamydiae is associated with earlier resolution of oviduct inflammation and a decreased Th17 Response. Presented at the Chlamydia Basic Research Society Meeting, March 21-23, 2009.
20. Pesek RD, Vargas PA, Jones SM, **\*\*\*\* AM**, McCracken A, Perry TT. Asthma prevalence and morbidity among urban and rural school children in Arkansas. *J Allergy Clin Immunol* 2009;123(2):808.
21. Jones SM, **\*\*\*\* AM**, Pons L, Kulis M, Perry TT, Steele P, Kamilaris J, Henry KA, Burks AW. Double-blind, placebo-controlled (DBPC) trial of oral immunotherapy (OIT) in peanut allergic children. *J Allergy Clin Immunol* 2009;123(2):814.
22. Chhabra S, Frazier EA, Perry TT, **\*\*\*\* AM**, Jones SM. Development of severe atopic disease in children after cardiac transplant. *J Allergy Clin Immunol* 2010;125(2):AB114.
23. Thyagarajan A, Jones SM, Kulis M, Smith PB, Steele PH, Kamilaris J, **\*\*\*\* AM**, Perry TT, Vickey B, Burks AW. Immunoglobulin changes using different dosing regimens of peanut oral immunotherapy (OIT) in peanut allergic subjects. *J Allergy Clin Immunol* 2010;125(2):AB21.
24. Steele PH, Kamilaris J, Edie AH, Pons L, Jones SM, **\*\*\*\* AM**, Perry TT, Burks AW. Peanut oral immunotherapy (OIT) modified rush: low dose vs high dose. *J Allergy Clin Immunol* 2010;125(2):AB21.
25. Jones SM, **\*\*\*\* AM**, Pons L, Perry TT, Morgan AR, Kulis M, Vickery B, Steele P, Kamilaris J, Hiegel AM, Burks AW. Double-blind, placebo-controlled trial of oral immunotherapy (OIT) in peanut (PN) allergic children: A follow-up. *J Allergy Clin Immunol* 2010;125(2):AB58.
26. Varshney P, Jones SM, Kulis M, Steele PH, Kemper AR, **\*\*\*\* AM**, Perry TT, Burks AW. Peanut oral immunotherapy (OIT) induces immunologic changes supporting the development of tolerance. *J Allergy Clin Immunol* 2010;125(2):AB59.
27. Bell MC, Stovall S, Harik NS, Perry TT, **\*\*\*\* AM**, Jones SM. Resistance patterns of microbes causing superinfection and antimicrobial prescribing practice in children with atopic dermatitis in a tertiary pediatric allergy clinic. *J Allergy Clin Immunol* 2010;125(2):AB92.
28. Woods JL, Rodriguez DM, Hensel DJ, Prodhan P, **\*\*\*\* AM**. Pelvic Inflammatory Disease in Adolescents: Do We Know Correct Diagnosis and Treatment Guidelines? Society for Adolescent Medicine Meeting April 2010.
29. Bailey SL, Woods JL, Hensel DJ, **\*\*\*\* AM**. Cervicitis in adolescents: Do we know the correct diagnosis and treatment guidelines? Oral presentation at National Association for Pediatric and Adolescent Gynecology Meeting April 2010.
30. **\*\*\*\* AM**, Frazer LC, Foote IP, Zurenski M, Andrews CW, O’Connell CM, Darville T. IL-23 promotes chlamydial clearance, Th1 immunity and pro-inflammatory cytokine responses following Chlamydia muridarum genital tract infection. Chlamydia Basic Research Society Meeting, March 21, 2011.
31. Cohane KP, Picard M, Lee A, Gierahn T, Calderon H, Geisler W, **\*\*\*\* AM**, Trupin S, Klausner J, Hook EW, Higgins DE, Siber G, Kohberger R, Flechtner JB. Identification of novel T- cell antigens through directed delivery of the *Chlamydia trachomatis* ORFeome to antigen presentation pathways in human monocyte-derived dendritic cells. Chlamydia Basic Research Society Meeting, March 21, 2011.
32. **\*\*\*\* AM**, Leung DYM, Sampson HA, Lindblad R, Liu AH, Wood RA, Jones SM, Burks AW, Stablein D, Sicherer SH. Association of Atopic Dermatitis (AD) Severity to Milk and Egg Allergy Outcomes in a Cohort of Atopic, Food-allergic Children (COFAR). *J Allergy Clin Immunol* 2011;126.
33. Vickery BP, **\*\*\*\* AM**, Steele PH, Kamilaris J, Hiegel AM, Carlisle SK, Perry TT, Jones SM, Burks AW. Early and Persistent Gastrointestinal Side Effects Predict Withdrawal from Peanut Oral Immunotherapy (OIT). *J Allergy Clin Immunol* 2011;87.
34. Kulis M, Varshney P, **\*\*\*\* AM**, Vickery BP, Perry TT, Jones SM, Burks AW. Peanut Oral Immunotherapy (OIT) Induces a Transient Increase in CD4+CD25+FoxP3+ Tregs and a Sustained Decrease of Th2-type Cytokines. *J Allergy Clin Immunol* 2011;97
35. Chervinskiy SK, Bondurant KL, Brodie-Fowler M, Perry TT, Jones SM, **\*\*\*\* AM**. Clinical features predicting primary immunodeficiency diseases. *J Invest Med* 2012; 432.
36. Jones SM, Burks AW, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, Henning AK, Vickery BP, Liu AH, **\*\*\*\* AM**, Shreffler WG, Plaut M, Sampson HA. A randomized, double-blind, placebo-controlled, multicenter trial of egg oral immunotherapy in children: An analysis of clinical tolerance. *J Allergy Clin Immunol* 2012; 245.
37. Burks AW, Vickery BP, **\*\*\*\* AM**, Steele P, Kamilaris J, Hiegel AM, Carlisle SK, Perry TT, Jones SM. Development of clinical tolerance after peanut OIT. *J Allergy Clin Immunol.* 2012;249.
38. Chin SJ, Kim EH, Kulis MD, Varshney P, Steele P, Kamilaris J, Hiegel A, Carlisle SK, **\*\*\*\* AM**, Smith PB, Vickery BP, Jones SM, Burks AW. Comparison of sublingual immunotherapy (SLIT) versus oral immunotherapy (OIT) in the treatment of peanut allergy. *J Allergy Clin Immunol* 2012; 532. (late-breaking abstract selection)
39. Dilley MA, Jones SM, **\*\*\*\* AM**, Perry TT, Pesek RD. Pneumococcal meningitis in a patient with IRAK-4 deficiency: A case of failed prophylactic therapy. *J Allergy Clin Immunol* 2013; 541.
40. Ward W, Casey P, Prodhan P, **\*\*\*\* AM**, Cranmer J. Two Decades of Mentoring: An effective model for successful promotion and career development. AAMC Group on Faculty Affairs conference, Minneapolis, MN, August 8, 2013.
41. Dilley M, Christie GL, Price M, Weeks C, Rettiganti M, Castro Melguizo M, **\*\*\*\* AM**, Perry TT, Pesek RD, Bell MC, Kennedy JL, O’Brien E, McGrath S, Hogan J, Patterson M, Aronson J, Casey P, Jones SM. Assessment Of Food Insecurity and Health Literacy In a Tertiary Care Pediatric Allergy Population. *J Allergy Clin Immunol* 2014;133:AB204.
42. O’Brien E, Gibbons T, **\*\*\*\* AM**, Oliver J, Rettiganti M, Castro Melguizo M, Chandler P, Fendley A, Casteel H, VonLanthen M, Fiedorek S, Perry T, Jones SM, Pesek R. Characteristics of Eosinophilic Esophagitis Among Children Living in Rural, Southern United States. *J Allergy Clin Immunol* 2014;133:AB259.
43. Jones SM**,** Burks AW, Wood RA, Fleischer DM, Sicherer SH, Henning AK, Lindblad RW, Dawson P, Vickery BP, Keet C, Liu AH, **\*\*\*\* AM**, Sampson HA. Long-lasting Egg Consumption in Egg Allergic Children Treated with Oral Immunotherapy (OIT): Follow-up from the Consortium of Food Allergy Research (CoFAR) Study. *J Allergy Clin Immunol* 2014;133:AB403. (late breaking abstract)
44. **\*\*\*\* AM**, Sikes JD, Payne JN, House SE, Jones SM. Pioglitazone Attenuates Peanut Induced Anaphylaxis in a Mouse Model of Peanut Allergy. *J Allergy Clin Immunol* 2015; 135 AB235.
45. Pesek RD, Gibbons T, **\*\*\*\* AM**, Rettiganti M, O'Brien E, Daniel C, Melguizo Castro M, C. Luo, Chandler PL, Fendley A, Perry TT, Bell MC, Kennedy JL, Jones SM. Prospective Analysis of Eosinophilic Esophagitis (EoE) in Pediatric Patients Living in Rural, Southeastern United States. *J Allergy Clin Immunol* 2015; 135 AB42.
46. Chiang D, Burks AW, Davidson W, Dawson P, Grishin A, Henning A, Jones SM, Leung DYM, Lindblad RW, Liu AH, **\*\*\*\* AM**, Sicherer SH, Vickery BP, Wood RA, Sampson HA, Berin C. Phenotypic Analysis of Peanut-Responsive T Cells at Baseline in Subjects Enrolled in CoFAR6, a Randomized Placebo-Controlled Epicutaneous Immunotherapy (EPIT) Trial for the Treatment of Peanut Allergy. *J Allergy Clin Immunol* 2015; 135:AB226.
47. Albin S, Fei K, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, Vickery BP, Liu AH, **\*\*\*\* AM**, Burks AW, Jones SM, Sampson HA, Berin C. Evaluation of Plasma Chemokines and Cytokines in the Setting of Egg Oral Immunotherapy (OIT). *J Allergy Clin Immunol* 2015; 135:AB26.
48. Sood A, **\*\*\*\* AM**, Rettiganti MR, Hiegel AM, Sikes JD, House SE, Payne JN, Bettis JL, Beckwith SE, Perry TT, Pesek RD, Kennedy JL, Chandler PL, Luo C, Jones SM. Oral Allergy Symptoms and Pollen sensitization in Tree Nut Allergic Subjects Receiving Walnut Oral Immunotherapy (WOIT). *J Allergy Clin Immunol* 2016;137: AB315.
49. **\*\*\*\* AM**, Rettiganti MR, Hiegel AM, Sood A, Daniel C, Beckwith SE, Bettis JL, Sikes JD, House SE, Payne JN, Pesek RD, Perry TT, Chandler PL, Kennedy JL, Luo C, Christie L, Jones SM. Desensitization to Walnut and Test Tree Nuts during a Double blind, Placebo Controlled Walnut Oral Immunotherapy Trial. *J Allergy Clin Immunol.* 2016; 137: AB 332.
50. Patterson M, Beckwith S, Rettiganti M, Luo C, Chandler P, Levy R, Casteel H, Vonlanthen M, Fiedorek S, **\*\*\*\* AM**, Jones SM, Pesek R. Tolerance of baked-milk in milk-triggered children with eosinophilic esophagitis (EoE). *J Allergy Clin Immunol* 2017;139:AB920.
51. **\*\*\*\* AM**, Rettiganti MR, Hiegel AM, Gibson ED, Beckwith S, House SE, Sikes JD, Chervinskiy SK, Pesek RD, Perry TT, Kennedy JL, Chandler P, Christie L, Luo C, Burks AW, Jones SM. Long-term Walnut Oral Immunotherapy Induces Clinically Relevant Treatment Responses in Tree Nut Allergic Children. *J Allergy Clin Immunol* 2017;139:AB318.
52. Stoner AN, Kennedy JL, Berlinski A, Jones SM, **\*\*\*\* AM**. Experience with Two Patients with Activated PI3K Delta Syndrome: Case Reports”. Presented at the American College of Allergy, Asthma and Immunology (ACAAI) National Conference, Boston, MA, October 2017.
53. Martin E, Patterson M, Beckwith S, Rettiganti M, Luo C, Chandler PL, Tootle C, Levy R, **\*\*\*\* AM**, Jones SM, Pesek RD. Bone mineral density screening in a pediatric population with eosinophilic esophagitis. *J Allergy Clin Immunol* 2018: 141(2):AB136.
54. Carlisle A, Bell A, Shelton E, Chandler PL, Chervinskiy SK, Hiegel AM, Kennedy JL, Perry TT, Jones SM, **\*\*\*\* AM**, Pesek RD. Safety of Mixed Tree Nut Oral Food Challenges in the Management of Multi-Tree Nut Allergic Children and Adolescents. *J Allergy Clin Immunol* 2018: 141(2):AB249.
55. Kim E, Jones SM, Burks AW, Wood RA, Sicherer SH, Leung DYM, Henning A, Lindblad RW, Dawson P, Keet C, **\*\*\*\* AM**, Sampson HA. A 5-year Summary of Real-life Dietary Egg Consumption after Completion of a 4-year Egg OIT Protocol. *J Allergy Clin Immunol* 2019:143 (2) AB82
56. **\*\*\*\* AM**, Lappereau-Gallot A, Green TD, Peillon A, Agbotounou W, Pongracic JA, Fleischer DM. Safety and tolerability of epicutaneous immunotherapy (EPIT) for peanut allergy: Analysis from two Phase 3 clinical trials. Oral Abstract Presentation: Novel Approaches to Immunotherapy. Abstract #: LBOA1699. European Academy of Allergy and Clinical Immunology Congress, Lisbon Portugal, June 3, 2019.
57. Jones SM, Burks AW, Sicherer SH, Leung DYM, Henning AK, Dawson P, Lindblad RW, **\*\*\*\* AM**, Kim E, Cho CB, Berin C, Davidson WF, Sampson HA, Wood RA. Impact of Epicutaneous Immunotherapy (EPIT) for the Treatment of Peanut Allergy in Children and Young Adults: Follow-up from the Consortium for Food Allergy Research (CoFAR) Study. EAACI Congress, Lisbon, Portugal, June 2019.
58. Jones SM, Kim EH, Nadeau KC, Nowak-Wegryzn A, Wood RA, Sampson HA, **\*\*\*\* AM,** Chinthrajah S, Johnson J, Spain K, Laurienzo-Panza J, Larson D, Plaut M, Qin T, Sanda S, Sever ML, Wheatley LM, Whitehouse D, Yan R, Burks AW for the Immune Tolerance Network (ITN). Tolerance Development Following Oral Immunotherapy (OIT) in 1-3 Year Old Children with Peanut Allergy: Findings from the Immune Tolerance Network (ITN) IMPACT TRIAL. AAAAI 2020 Annual Meeting, Philadelphia, PA. (late breaking oral abstract selection) *J Allergy Clin Immunol*, AB338, Feb 2020
59. **\*\*\*\* AM**, Fleischer DM, Chinthrajah S, Campbell DE, Green TD, Bee KJ, Peillon A, Ochletree T, Sampson HA. An Evaluation of Factors Influencing Response to Epicutaneous Immunotherapy for Peanut Allergy in the PEPITES Trial. American College of Allergy, Asthma and Immunology (ACAAI) 2020 Virtual Annual Meeting, e-poster/oral abstract presentation.
60. Aluri J, Bach A, Kaviany S, Chiquetto Paracatu L, Kitcharoensakkul M, Walkiewicz M, Putnam C, Shinawi M, Saucier N, Rizzi E, Harmon M, Keppel M, Ritter M, Similuk M, Kulm E, Joyce M De Jesus A, Goldbach-Mansky R, Lee Y, Cella M, Kendall P, Dinauer M, Bednarski J, Bemrich-Stolz C, Canna S, Abraham S, Demczko M, Powell J, Jones S, **\*\*\*\* AM**, De Ravin S, Bleesing J, Connelly J, Rao VK, Schuettlpelz LG, Cooper MA. Mosaic and Germline Gain-Of-Function Variants In TLR8 Leading To Immunodeficiency With Lymphoproliferation And Bone Marrow Failure. 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference. Journal of Clinical Immunology (2021) 41 (Suppl 1):S1–S135.
61. Rogers AL, Seminara EJ, Jin J, Murphy C, Sood A, Munoz-Mendoza D, Manegold E, Whitaker BN, Roberson P, Jones SM, **\*\*\*\* AM**. Assessment of Anxiety, Depression and Resilience

in Food-Allergic Adolescents and Primary Caregivers During the COVID-19 Pandemic. AAAAI 2021 Virtual Annual Meeting, e-poster/oral abstract presentation.

1. Beyer K, Abbas A, Blumchen K, Trujillo JE, Sharma V, Deschildre A, **\*\*\*\* AM**, Muraro A, Nilsson C, Ibañez MD, Brown K, Casale TB. Trial in Progress (TiP) abstract, “Longer-Term Safety Outcomes of Defatted Powder of Arachis Hypogaea L., Semen (Peanuts) in Subjects From Prior Clinical Trials (ARC008): A Trial-in-Progress and Preliminary Insights”, European Academy of Allergy and Clinical Immunology Hybrid Congress 2021. Krakow, Poland, 10 – 12 July 2021.
2. Vickery BP, du Toit G, Ratnayake A, Blumchen K, Sharma V, Chapman J, Deschildre A, Sher L, Norval D, Adelman DC, Beyer K, Casale TB, Greiner A, Cox A, Robison RG, Brown KR, **\*\*\*\* AM**. Baseline Clinical and Immunologic Characteristics of Children Screened in the Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON) Trial. Abstract submitted for AAAAI 2022 Annual Meeting, Phoenix, AZ, February 25-28, 2022.
3. Robison RG, Pongracic JA, Bird JA, **\*\*\*\* AM**, Bee KJ, Campbell DE, Meney J, Peillon A, Sampson HA, Fleischer DM. Pooled Safety Data from Phase 3 Studies of Epicutaneous Immunotherapy for Peanut Allergy in Children Aged 4-11 years. Abstract submitted for AAAAI 2022 Annual Meeting, Phoenix, AZ, February 25-28, 2022.
4. Price AS, Rogers AL, Seminara EJ, Patel N, Samandi LZ, Jin J, Roberson PK, Whitaker BN, Manegold EM, Murphy C, Sood AK, Munoz-Mendoza D, Parrish CP, Bird JA, Jones SM, **\*\*\*\* AM**. A Multi-Center Evaluation of Anxiety, Depression, and Resilience in Food Allergic Adolescents and Primary Caregivers during the COVID-19 Pandemic. Abstract submitted for AAAAI 2022 Annual Meeting, Phoenix, AZ, February 25-28, 2022.
5. Patel N, Samandi LZ, Price AS, Rogers AL, Seminara EJ, Whitaker BN, Sood AK, Munoz- Mendoza D, Jin J, Roberson PK, Parrish CP, Jones SM, **\*\*\*\* AM**, Bird JA. A Multi-Center Assessment of Food Allergy Quality of Life in Adolescents and Caregivers in Relation to Anxiety and Depression During the COVID-19 Pandemic. Abstract submitted for AAAAI 2022 Annual Meeting, Phoenix, AZ, February 25-28, 2022.

# Local/Regional Meetings:

1. **\*\*\*\* AM**, Bhutta AT, Heulitt MJ, Harville TO, Burks AW, Jones SM. Near-Fatal *Pneumocystis Carinii* pneumonia in a previously immunocompetent infant treated with high-dose corticosteroids. *J Clin Invest*, 2001;49:97A.

1. **\*\*\*\* AM**, Vargas PA, Feild CR, Simpson PM, Wheeler JG, Barrett KW, Flick EL, Jones SM. Assessment of pediatric asthma awareness among head start staff. *J Clin Invest*; 2002.
2. Bailey AE, Bleesing JJH, Jones SM, Perry TT, Nagarajan UM, **\*\*\*\* AM**. Major histocompatibility complex case II deficiency in a child with CD4 lymphopenia, hypogammaglobulinemia, a recurrent pneumonia, and enteroviral meningitis. *J Invest Med* 2007;16:S249.
3. Jordan TJ, Jones SM, Perry TT, Palmer KP, Bleesing JJH, Lyle RE, **\*\*\*\* AM**. Immunologic Profile of a Preterm Neonate with Immune Deficiency Polyendocrinopathy Enteropathy, X-linked (IPEX) Syndrome. Pediatric Summit, September 6, 2007.
4. Bailey AE, Bleesing JJH, Jones SM, Perry TT, Palmer KP, Nagarajan UM, **\*\*\*\* AM**. Major Histocompatibility Complex Class II Deficiency in a Child with CD4 Lymphopenia, Hypogammaglobulinemia , Recurrent Pneumonia, and Enteroviral Meningitis. Pediatric Summit, September 6, 2007.
5. Haynes A, **\*\*\*\* AM**, Jones SM, Palmer KP, Hall P, Perry TT. Prolonged Eosinophilia and Respiratory Failure Associated with Visceral Larva Migrans. Pediatric Summit, September 6, 2007.
6. Jordan TJ, Jones SM**,** Perry TT, Palmer KP, Lyle RE, Bleesing JJ, **\*\*\*\* AM**. A preterm infant with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. *J Invest Med* 2008;56(1):406.
7. Bailey AE, Bleesing JJH, Jones SM, Perry TT, Nagarajan UM, **\*\*\*\* AM**. Major histocompatibility complex case II deficiency in a child with CD4 lymphopenia, hypogammaglobulinemia, a recurrent pneumonia, and enteroviral meningitis. *J Invest Med* 2007;16:S249.
8. Short JA, Morris PK, **\*\*\*\* AM**. Treatment of Polyarthritis with Etanercept in a Patient with X-linked Agammaglobulinemia. *J Invest Med 2008*; 56(1): 361. *(Received AFMR/Centocor Scholar in Rheumatology Award)*
9. Pesek RD, Perry TT, **\*\*\*\* AM**, Jones SM, Hall RW, Palmer KP. An Infant with Partial DiGeorge Syndrome, CHARGE Association, and Congenital Microgastria. *J Invest Med* 2008; 56(1): 360.
10. Haynes AD, Lal A, **\*\*\*\* AM**, Jones SM, Palmer KP, Hall P, Perry TT. Prolonged Eosinophilia and Respiratory Failure Associated with Visceral Larvae Migrans. *J Invest Med* 2008;56(1):358.
11. Kloepfer K, Perry T, **\*\*\*\* AM**, Palmer K, Jones SM. Use of Abatacept to treat immune thrombocytopenia to treat common variable immunodeficiency. *J Invest Med* 2008;56(1):406.
12. Kennedy J, Perry T, **\*\*\*\* AM**, Palmer K, Simmons L, Schellhase D, Jones SM. Association of steroid-dependent asthma, immunodeficiency and Cowden syndrome in a family cohort. *J Invest Med* 2008;56(1):406.
13. Bell MC, Perry TT, **\*\*\*\* AM**, Jones SM. X-linked agammaglobulinemia with isolated IgM deficiency. *J Invest Med* 2009.
14. Freeman CL, **\*\*\*\* AM**, Jones SM, Perry TT. Complications associated with *Toxocara canis*

infection in three pediatric patients. *J Invest Med* 2009.

1. Petitto J, Perry TT, Schaefer GB, Jones SM, **\*\*\*\* AM**. Novel chromodomain helicase DNA binding protein 7 gene mutation associated with CHARGE and Atypical, Complete DiGeorge Syndromes. Southern Society for Pediatric Research February 17, 2011. *J Invest Med* 2011.
2. Anvari S, Hall PL, Perry TT, **\*\*\*\* AM**, Bufford JD, Jones SM. Influenza Vaccine Testing and Administration in Egg Allergic Children. Southern Society for Pediatric Research. *J Invest Med* 2011.
3. Cranmer JM, Ward WL, Hale RB, **\*\*\*\* AM**. Two Decades of Faculty Mentoring: An Effective Model for Successful Promotion and Career Development. UAMS Women in Research Poster Showcase- October 30, 2014